Workshop on Short-term Carcinogenicity Testing by unknown
Br. J. Cancer (1976) 34, 674
Report of meeting
WORKSHOP ON SHORT-TERM CARCINOGENICITY TESTING
(Organized by Professor David Harnden)
A workshop was held on 23 June 1976
in the University of Birmingham, to discuss
the present status of short-term tests for
carcinogens. The meeting, which was jointly
sponsored by the British Association for
Cancer Research and the European Environ-
mental Mutagen Society (British Section),
was attended by approximately 80 people
from these 2 societies, from industry and
from government agencies. It opened with
short statements by Dr Ken Williamson and
Professor Bryn Bridges setting out the
industrial and scientific backgrounds to the
field. Short papers were then delivered on
the various mutagenicity tests: bacterial
mutagenicity (Dr Colin Garner), cytogenetic
tests (Dr David Scott), DNA repair (Dr
Michael Green), mouse dominant lethal tests
(Dr Ian Purchase). In the afternoon, other
tests not based directly on mutagenicity
were considered: cellular transformation (Dr
Jerry Styles), degranulation of microsomes
(Dr Ian Purchase, stepping in at the last
minute in place of Professor Bob Rabin),
biphenyl 2-hydroxylation (Dr Jim Bridges),
the relationship between these tests and
conventional animal testing (Dr Len Levy)
and epidemiology (Dr Leo Kinlen). There
were several long discussion periods w-ith
lively, sometimes vigorous, debate. No
specific attempt was made to reach conclu-
sions or to draft a statement. Nevertheless,
a number of useful areas of agreement did
emerge, some difficulties were highlighted and
some interesting concepts introduced.
Areas of Agreement
(1) There was no serious dissent from the
view that some of the short-term tests will
have a place in the testing of carcinogens.
(2) No one test provides an overall screen
for carcinogenic activity, and combinations
of tests will be necessary to achieve a usable
degree of confidence.
(3) There was at least a measure of agree-
ment that there should be different standards
for compounds to which large sections of the
population will be exposed (e.g. drugs, pesti-
cides and food additives) and for those com-
pounds which are used in manufacturing
processes but which do not become a com-
ponent of the end product, at least not in
active form.
(4) The short-term tests measure only the
potential of a compound as a mutagen (or
carcinogen) and it is vitally important also
to consider the nature and level of exposure,
and the probability that the compound will
in fact reach a sensitive tissue.
Difficulties
(1) Comparisons tend to be made between
short-term tests and " known carcinogeni-
city". This usually means carcinogenicity
in animals. It was, however, pointed out
that, since there is considerable variation
between the sensitivity of different animal
species to a particular compound, and since
man can be regarded simply as another
mammalian species, a particular result from
an animal test cannot be transposed directly
to man. Stress was also placed on the
inadequacy of much existing data on animal
carcinogenicity. It seemed unwise therefore,
to put special weight on animal tests (except
in so far as required by current legislation)
but rather to regard animal tests as part of
a more comprehensive system of testing.
(2) All the tests fall short of 100%
accuracy. All would miss some carcinogens:
all would give some false positives. Since
the large majority of compounds tested
would be likely to be non-carcinogenic, even
a low percentage of false positives could
cause serious problems.
(3) There was a lack of information about
correlations between tests, and corroboration
oftest results in different laboratories. It was
stressed by some speakers that there are
certainly some areas where the tests do not
correlate. An appeal was made to draw up
tabulations of such correlations, but no
conclusion was reached as to how this should
be done.REPORT OF MEETING
(4) Epidemiological evidence, though
valuable, and ultimately the only real proof,
took many years, maybe decades, to collect
(largely because of very long latent periods)
and sometimes the risk had actually disap-
peared before its occurrence in former years
was recognized. Particular difficulty is ex-
perienced when the effect is on an already
common tumour. Many felt this to be a
powerful argument in favour of the short-
term tests, but clearly, at the present stage,
information about the correlation between
epidemiological evidence and the results of
short-term tests is urgently required.
Useful concepts
(1) Tiered testing.-The idea that the
technically simpler tests (probably more
than one for each compound) should be used
as preliminary screens, to be followed by the
more complex and costly tests, and ulti-
mately studies on man, was considered
favourably, but no attempt was made to
define what the structure of such a tiered
system should be.
(2) Acceptable risk.-The concept of " ac-
ceptable level ofrisk " seemed more appropri-
ate than the concept of " banning "; there
being in many cases a necessity to balance
benefit against hazard (the example of
ionizing radiation was quoted). There would
clearly be difficulty in defining what is
acceptable. The fear of a ban could lead
to erroneous and hasty judgements.
General points on the tests
(1) The bacterial tests (both the muta-
genicity and the DNA repair tests) seemed
to be generally considered as useful.
(2) The chromosome-based tests were
thought by some not to be so useful at this
stage, being time consuming and hard to
interpret.
(3) The DNA repair test with human
fibroblasts seems very promising, but is at
an early stage of development.
(4) The dominant lethal test in mice was
found to be exceptionally expensive, and
moreover was very difficult to interpret. It
was also pointed out that the test was of no
value unless there was more evidence that the
compound under test, or a metabolite,
reached the testis.
(5) Cellular transformation was regarded
as technically difficult. The use of cloning in
soft agar seemed to offer some advantage
over morphological transformation of con-
ventional cell culture. The potential of such
transformed cells (either in suspension or
monolayer culture) to form tumours had not
been adequately tested.
(6) Degranulation of microsomes at
present seems less satisfactory than the
bacterial assays. For example, it is not good
for the polycyclic hydrocarbons. This raised
the useful idea that some tests might be
more appropriate than others for specific
classes or compounds.
(7) The 2-hydroxylation of biphenyl
again may have its place for specific classes
of compound. It seems particularly good for
the polycyclic hydrocarbons.
(8) At this stage, the short-term tests
should not be regarded as quantitative.
(9) Several tests had not been considered
adequately at the workshop: (a) specific
locus mutation in yeast, (b) recessive lethal
mutation in Drosophila, (c) mutation of
human and other mammalian cells in culture.
(10) There was a need to consider the
relevance of tests with pure compounds to
the human situation, where many carcino-
gens will be present in complex mixtures.
Points regarding legislation
(1) Thoughl not required, bacterial test
evidence is already sometimes submitted and
considered as supportive evidence in drug
registration.
(2) Three EEC directives are in prepara-
tion and these are known to be fairly specific
in their recommendations. Great concern
was expressed that legislation might be
imposed by regulatory bodies, without ade-
quate consideration by groups of experts
within the UK, such as those present at the
workshop. Positive steps should be taken
now to examine these directives and ensure
that they are acceptable to British scientists
and industrialists.
Conclusion
No attempt was made to reach a firm
conclusion. The main outcome was that the
present situation should be kept under
review.
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